Prefer Torrent Pharma, Ipca Labs among midcap pharma names: Sudip Bandyopadhyay

In a chat with ET Now, Sudip Bandyopadhyay, President, Destimoney Securities, shares his view on pharma space.

ET Now: What is your view on mid and largecap pharma stocks? There are some niche players in the pharma pack as well.

Sudip Bandyopadhyay: We continue to like pharma sector. The currency depreciation was have seen of late may continue over the next few months. This should definitely help drug makers one way or the other. The domestic pharma sector is a long-term growth story. We have extremely bullish view on pharma stocks. One has to be wary of valuations.

Among different segments, we continue to focus on the midcap pharma space because we believe that still there is lot of value sitting there. Torrent Pharma is what we like at this stage. We continue to like Ipca Labs, and Dishman. In addition, there are a lot of opportunities like Natco even as the stock has moved up quite a bit. Still it continues to look attractive.

ET Now: Whenever I think of about pharma sector with you, I think of Wockhardt. Yours was an amazing prediction. Would you like to say something on it?

Sudip Bandyopadhyay: Yes, that prediction paid investors handsomely. But, I would not buy Wockhardt today. Overall, pharma space has been an interesting journey as far as the domestic capital market is concerned.